Pharmosa Biopharm announced on the 13th that its licensing partner Liquidia Corporation (LQDA) plans to host an R&D Day in September–October this year to release the latest results from the open-label Phase III clinical trial of L606, an investigational therapy for pulmonary arterial hypertension (PAH, WHO Group I). The company expressed optimism about the upcoming milestone.

General Manager Pei Kan stated that L606, an inhaled therapy developed by Pharmosa Biopharm, utilizes long-acting liposomal inhalation technology, offering stable dosing and improved patient adherence. The drug is being developed for the treatment of both PAH (WHO Group I) and pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group III).

L606 has been licensed to LQDA for development and commercialization in North America, with the agreement expanded last year to include Europe and Japan. The total deal value could reach up to USD 386 million, along with double-digit royalty sharing on sales.

During LQDA’s second-quarter corporate update, the company disclosed plans to present the latest Phase III open-label trial results for L606 in PAH at its September–October R&D Day, including one-year clinical data to highlight the drug’s therapeutic advantages.

Kan noted that with the successful U.S. launch of LQDA’s own product Yutrepia, a short-acting inhaled dry powder therapy, the partner has demonstrated strong drug development and commercialization capabilities. LQDA is also preparing to initiate a global pivotal Phase III trial of L606 for PH-ILD by the end of this year. Looking ahead, additional potential indications for L606 are under evaluation, aiming to further enhance its market value and provide innovative therapeutic options for patients worldwide suffering from pulmonary hypertension and related conditions.

Resource: 授權夥伴擬 9～10 月公布L606三期數據 國邑*樂觀看待